The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Notch signaling: An emerging therapeutic target for cancer treatment
Open accessAbstract
The Notch pathway is involved in cell proliferation, differentiation and survival. The Notch signaling pathway is one of the most commonly activated signaling pathways in cancer. Alterations include activating mutations and amplification of the Notch pathway, which play key roles in the progression of cancer. Accumulating evidence suggests that the pharmacological inhibition of this pathway can overcome chemoresistance. Efforts have been taken to develop Notch inhibitors as a single agent or in combination with clinically used chemotherapeutics to treat cancer. Some Notch inhibitors have been demonstrated to have therapeutic efficacy in preclinical studies. This review summarizes the recent studies and clinical evaluations of the Notch inhibitors in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulatory networks defining EMT during cancer initiation and progression
Craene, B. D., & Berx, G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3447 · Cited by 2,487
Timmerman, L. A., Grego-Bessa, J., Raya, A., Bertrán, E., Pérez-Pomares, J. M., Díez, J., Aranda, S., Palomo, S., McCormick, F., Izpisúa-Belmonte, J. C., et al. (2004) · Genes & Development · doi:10.1101/gad.276304 · Cited by 985
Notch signalling in solid tumours: a little bit of everything but not all the time
Ranganathan, P., Weaver, K. L., & Capobianco, A. J. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3035 · Cited by 824
Therapeutic antibody targeting of individual Notch receptors
Wu, Y., Cain-Hom, C., Choy, L., Hagenbeek, T. J., de Leon, G. P., Chen, Y., Finkle, D., Venook, R., Wu, X., Ridgway, J., et al. (2010) · Nature · doi:10.1038/nature08878 · Cited by 720
Therapeutic modulation of Notch signalling — are we there yet?
Andersson, E. R., & Lendahl, U. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4252 · Cited by 457
Targeting Notch signaling pathway in cancer: Clinical development advances and challenges
Takebe, N., Nguyen, D., & Yang, S. X. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.09.005 · Cited by 413
Alterations of the Notch pathway in lung cancer
Westhoff, B., Colaluca, I. N., D'Ario, G., Donzelli, M., Tosoni, D., Volorio, S., Pelosi, G., Spaggiari, L., Mazzarol, G., Viale, G., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907781106 · Cited by 387
Slug is a direct Notch target required for initiation of cardiac cushion cellularization
Niessen, K., Fu, Y., Chang, L., Hoodless, P. A., McFadden, D., & Karsan, A. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200710067 · Cited by 363
Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy
McAuliffe, S. M., Morgan, S. L., Wyant, G. A., Tran, L. T., Muto, K. W., Chen, Y. S., Chin, K. T., Partridge, J. C., Poole, B. B., Cheng, K.-H., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206400109 · Cited by 328
Krop, I., Demuth, T., Guthrie, T., Wen, P. Y., Mason, W. P., Chinnaiyan, P., Butowski, N., Groves, M. D., Kesari, S., Freedman, S. J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.1540 · Cited by 318
The Notch signaling pathway as a mediator of tumor survival
Capaccione, K. M., & Pine, S. R. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt127 · Cited by 296
Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors
Schott, A. F., Landis, M. D., Dontu, G., Griffith, K. A., Layman, R. M., Krop, I., Paskett, L. A., Wong, H., Dobrolecki, L. E., Lewis, M. T., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3326 · Cited by 277
Tolcher, A. W., Messersmith, W. A., Mikulski, S. M., Papadopoulos, K. P., Kwak, E. L., Gibbon, D. G., Patnaik, A., Falchook, G. S., Dasari, A., Shapiro, G. I., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.8282 · Cited by 268
Yuan, X., Wu, H., Han, N., Xu, H., Chu, Q., Yu, S., Chen, Y., & Wu, K. (2014) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0087-z · Cited by 248
Self-citationMessersmith, W. A., Shapiro, G. I., Cleary, J. M., Jimeno, A., Dasari, A., Huang, B., Shaik, M. N., Cesari, R., Zheng, X., Reynolds, J. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0607 · Cited by 218
Liu, Y.-P., Yang, C.-J., Huang, M.-S., Yeh, C.-T., Wu, A. T. H., Lee, Y.-C., Lai, T.-C., Lee, C.-H., Hsiao, Y.-W., Lu, J., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1733 · Cited by 210
The mouse mammary tumor associated gene INT3 is a unique member of the NOTCH gene family (NOTCH4)
Gallahan, D., & Callahan, R. (1997) · Oncogene · doi:10.1038/sj.onc.1201035 · Cited by 196
Wei, P., Walls, M., Qiu, M., Ding, R., Denlinger, R. H., Wong, A., Tsaparikos, K., Jani, J. P., Hosea, N., Sands, M., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0034 · Cited by 195
Hales, E. C., Taub, J. W., & Matherly, L. H. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2013.09.021 · Cited by 187
Inhibition of Notch Signaling by a γ-Secretase Inhibitor Attenuates Hepatic Fibrosis in Rats
Chen, Y., Zheng, S., Qi, D., Zheng, S., Guo, J., Zhang, S., & Weng, Z. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046512 · Cited by 168
Fouladi, M., Stewart, C. F., Olson, J., Wagner, L. M., Onar-Thomas, A., Kocak, M., Packer, R. J., Goldman, S., Gururangan, S., Gajjar, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.7806 · Cited by 164
Wang, K., Zhang, Q., Li, D., Ching, K. A., Zhang, C., Zheng, X., Ozeck, M., Shi, S. T., Li, X., Wang, H., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1348 · Cited by 155
Sureban, S. M., May, R. J., Mondalek, F. G., Qu, D., Ponnurangam, S., Pantazis, P., Anant, S., Ramanujam, R. P., & Houchen, C. W. (2011) · Journal of Nanobiotechnology · doi:10.1186/1477-3155-9-40 · Cited by 154
A phase II study of RO4929097 in metastatic colorectal cancer
Strosberg, J., Yeatman, T. J., Weber, J., Coppola, D., Schell, M. J., Han, G., Almhanna, K., Kim, R. D., Valone, T., Jump, H., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.02.056 · Cited by 148
Pandya, K., Meeke, K., Clementz, A. G., Rogowski, A., Roberts, J., Miele, L., Albain, K. S., & Osipo, C. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.321 · Cited by 140
Yabuuchi, S., Pai, S. G., Campbell, N. R., de Wilde, R. F., Oliveira, E. D., Korangath, P. C., Streppel, M. M., Rasheed, Z. A., Hidalgo, M. M., Maitra, A., et al. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.01.054 · Cited by 140
D'Angelo, R. C., Ouzounova, M., Davis, A., Choi, D., Tchuenkam, S. M., Kim, G., Luther, T. K., Quraishi, A. A., Şenbabaoğlu, Y., Conley, S. J., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0228 · Cited by 139
Saito, N., Fu, J., Zheng, S., Yao, J., Wang, S., Liu, D. D., Yuan, Y., Sulman, E. P., Lang, F. F., Colman, H., et al. (2013) · Stem Cells · doi:10.1002/stem.1528 · Cited by 133
Prognostic impact of Notch ligands and receptors in nonsmall cell lung cancer
Dønnem, T., Andersen, S., Al-Shibli, K. I., Al‐Saad, S., Busund, L., & Bremnes, R. M. (2010) · Cancer · doi:10.1002/cncr.25551 · Cited by 131
EGFR Blockade Enriches for Lung Cancer Stem–like Cells through Notch3-Dependent Signaling
Arasada, R. R., Amann, J. M., Rahman, M. A., Huppert, S. S., & Carbone, D. P. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3724 · Cited by 128
Yuan, X., Wu, H. K., Xu, H., Han, N., Chu, Q., Yu, S., Chen, Y., & Wu, K. (2015) · Scientific Reports · doi:10.1038/srep10338 · Cited by 122
Self-citationMaraver, A., Fernández-Marcos, P. J., Herranz, D., Cañamero, M., Muñoz‐Martín, M., Goméz-López, G., Mulero, F., Megı́as, D., Sänchez‐Carbayo, M., Shen, J., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.014 · Cited by 122
Zou, J., Peng, L., Lu, F., Liu, N., Dai, J., Ye, J., Qu, X., Sun, X., Ma, D., Park, J., et al. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-3 · Cited by 121
Constitutive Notch2 signaling induces hepatic tumors in mice
Dill, M. T., Tornillo, L., Fritzius, T., Terracciano, L., Semela, D., Bettler, B., Heim, M. H., & Tchorz, J. S. (2012) · Hepatology · doi:10.1002/hep.26165 · Cited by 115
Jesus‐Acosta, A. D., Laheru, D. A., Maitra, A., Arcaroli, J. J., Rudek, M. A., Dasari, A. N., Blatchford, P. J., Quackenbush, K. S., & Messersmith, W. A. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0083-8 · Cited by 111
Allen, T. D., Rodriguez, E. M., Jones, K. D., & Bishop, J. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0595 · Cited by 111
Li, Y., Zhang, J., Ma, D., Zhang, L., Si, M., Yin, H., & Li, J. (2012) · FEBS Journal · doi:10.1111/j.1742-4658.2012.08607.x · Cited by 109
Bmi1 regulates murine intestinal stem cell proliferation and self-renewal downstream of Notch
López‐Arribillaga, E., Rodilla, V., Pellegrinet, L., Guiu, J., Iglesias, M., Román, Á., Gutarra, S., González, S., Muñoz‐Cánoves, P., Fernández‐Salguero, P. M., et al. (2014) · Development · doi:10.1242/dev.107714 · Cited by 107
Honokiol in Combination with Radiation Targets Notch Signaling to Inhibit Colon Cancer Stem Cells
Ponnurangam, S., Mammen, J. M. V., Ramalingam, S., He, Z., Zhang, Y., Umar, S., Subramaniam, D., & Anant, S. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0999 · Cited by 107
Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma
Cook, N., Frese, K. K., Bapiro, T. E., Jacobetz, M. A., Gopinathan, A., Miller, J. L., Rao, S. S., Demuth, T., Howat, W., Jodrell, D. I., et al. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20111923 · Cited by 103
Phase 2 study of RO 4929097, a gamma‐secretase inhibitor, in metastatic melanoma: SWOG 0933
Lee, S. M., Moon, J., Redman, B. G., Chidiac, T. A., Flaherty, L. E., Zha, Y., Othus, M. K. D., Ribas, A., Sondak, V. K., Gajewski, T. F., et al. (2014) · Cancer · doi:10.1002/cncr.29055 · Cited by 91
Expression of Notch1 Correlates with Breast Cancer Progression and Prognosis
Yuan, X., Zhang, M., Wu, H. K., Xu, H., Han, N., Chu, Q., Yu, S., Chen, Y., & Wu, K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131689 · Cited by 82
Self-citationRichter, S., Bedard, P. L., Chen, E. X., Clarke, B. A., Tran, B., Hotte, S. J., Stathis, A., Hirte, H. W., Razak, A. R. A., Reedijk, M., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-9965-4 · Cited by 80
Ramakrishnan, V. G., Ansell, S. M., Haug, J., Grote, D. M., Kimlinger, T. K., Stenson, M. J., Timm, M., Wellik, L. E., Halling, T. M., Rajkumar, S. V., et al. (2011) · Leukemia · doi:10.1038/leu.2011.192 · Cited by 78
Notch inhibition allows oncogene-independent generation of iPS cells
Ichida, J. K., Julia, T. C. W., Williams, L. A., Carter, A. C., Shi, Y., Moura, M. T., Ziller, M. J., Singh, S., Amabile, G., Bock, C., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1552 · Cited by 77
The Novel Gamma Secretase Inhibitor RO4929097 Reduces the Tumor Initiating Potential of Melanoma
Huynh, C., Poliseno, L., Segura, M. F., Medicherla, R. C., Haimovic, A., Menéndez, S., Shang, S., Pavlick, A. C., Shao, Y., Darvishian, F., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025264 · Cited by 76
Sahebjam, S., Bedard, P. L., Castonguay, V., Chen, Z., Reedijk, M., Liu, G., Cohen, B. L., Zhang, W.-J., Clarke, B. A., Zhang, T., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.380 · Cited by 75
Zhang, C. C., Pavlíček, A., Zhang, Q., Lira, M. E., Painter, C. L., Yan, Z., Zheng, X., Lee, N. V., Ozeck, M., Qiu, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1379 · Cited by 74
López‐Guerra, M., Xargay‐Torrent, S., Rosich, L., Montraveta, A., Roldán, J., Matas‐Céspedes, A., Villamor, N., Aymerich, M., López-Otín, C., Pérez‐Galán, P., et al. (2014) · Leukemia · doi:10.1038/leu.2014.143 · Cited by 69
Ban, J., Aryee, D. N. T., Fourtouna, A., van der Ent, W., Kauer, M., Niedan, S., Machado, I., Galindo, C. R., Tirado, Ò. M., Schwentner, R., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1736 · Cited by 69
Molecular Pathways: Context-Dependent Approaches to Notch Targeting as Cancer Therapy
Egloff, A. M., & Grandis, J. R. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2258 · Cited by 69
Azzam, D. J., Zhao, D., Sun, J., Minn, A. J., Ranganathan, P., Drews‐Elger, K., Han, X., Picon‐Ruiz, M., Gilbert, C. A., Wander, S. A., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302558 · Cited by 67
Pharmacologic inhibition of vacuolar H+ ATPase reduces physiologic and oncogenic Notch signaling
Kobia, F., Duchi, S., Deflorian, G., & Vaccari, T. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.11.002 · Cited by 67
Palagani, V., Bozko, P. M., Khatib, M. E., Belahmer, H., Giese, N. A., Sipos, B., Malek, N. P., & Plentz, R. R. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt394 · Cited by 67
Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells
Debeb, B. G., Cohen, E. N., Boley, K. M., Freiter, E. M., Li, L., Robertson, F. M., Reuben, J. M., Cristofanilli, M., Buchholz, T. A., & Woodward, W. A. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2075-8 · Cited by 65
Aspartate β-hydroxylase expression promotes a malignant pancreatic cellular phenotype
Dong, X., Lin, Q., Aihara, A., Li, Y., Huang, C.-K., Chung, W., Tang, Q., Chen, X., Carlson, R. I., Nadolny, C., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2840 · Cited by 64
Mittal, S., Sharma, A., Andugulapati, S. B., Gowda, M. C., Dighe, R. R., Kumar, R. V., & Rangarajan, A. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0280 · Cited by 61
Delta-Like Ligand 4–Notch Blockade and Tumor Radiation Response
Liu, S. K., Bham, S. A. S., Fokas, E., Beech, J. S., Im, J. H., Cho, S., Harris, A. L., & Muschel, R. J. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr419 · Cited by 60
Miles, K. M., Seshadri, M., Ciamporcero, E. S., Adelaiye-Ogala, R. M., Gillard, B. M., Sotomayor, P. C., Attwood, K. M., Shen, L., Conroy, D., Kuhnert, F., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112371 · Cited by 59
Chu, Q., Orr, B. A., Semenkow, S., Bar, E. E., & Eberhart, C. G. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2119 · Cited by 59
Self-citationDíaz-Padilla, I., Hirte, H. W., Oza, A. M., Clarke, B. A., Cohen, B. L., Reedjik, M., Zhang, T., Kamel‐Reid, S., Ivy, S. P., Hotte, S. J., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-0001-5 · Cited by 58
Giovannini, C., Baglioni, M., Toaldo, M. B., Ventrucci, C., D’Adamo, S., Cipone, M., Chieco, P., Gramantieri, L., & Bolondi, L. (2013) · Oncotarget · doi:10.18632/oncotarget.1221 · Cited by 52
Jenkins, D. W., Ross, S. J., Veldman-Jones, M. H., Foltz, I. N., Clavette, B. C., Manchulenko, K., Eberlein, C., Kendrew, J., Petteruti, P., Cho, S., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-1027 · Cited by 52
γ-Secretase inhibitor enhances antitumour effect of radiation in Notch-expressing lung cancer
Mizugaki, H., Sakakibara‐Konishi, J., Ikezawa, Y., Kikuchi, J., Kikuchi, E., Oizumi, S., Dang, T. P., & Nishimura, M. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.178 · Cited by 51
Rosati, E., Sabatini, R., Falco, F. D., Papa, B. D., Falzetti, F., Ianni, M. D., Cavalli, L., Fettucciari, K., Bartoli, A., Screpanti, I., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27863 · Cited by 50
Kuramoto, T., Goto, H., Mitsuhashi, A., Tabata, S., Ogawa, H., Uehara, H., Saijo, A., Kakiuchi, S., Maekawa, Y., Yasutomo, K., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0640 · Cited by 49
Notch1-induced T cell leukemia can be potentiated by microenvironmental cues in the spleen
Ma, S., Shi, Y., Pang, Y., Dong, F., Cheng, H., Hao, S., Xu, J., Zhu, X., Yuan, W., Cheng, T., et al. (2014) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0071-7 · Cited by 47
Wang, X., He, Z., Xia, T., Li, X., Liang, D., Lin, X., Wen, H., & Lan, K. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1467 · Cited by 45
Jiang, L., Zhang, X., Du, P., & Zheng, J. (2011) · Chinese Journal of Cancer Research · doi:10.1007/s11670-011-0140-1 · Cited by 42
Séveno, C., Loussouarn, D., Bréchet, S., Campone, M., Juin, P. P., & Barillé‐Nion, S. (2012) · Breast Cancer Research · doi:10.1186/bcr3214 · Cited by 42
Arcaroli, J. J., Quackenbush, K. S., Purkey, A., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.361 · Cited by 41
Yu, P., Petrus, M., Ju, W., Zhang, M., Conlon, K. C., Nakagawa, M., Maeda, M., Bamford, R. N., & Waldmann, T. A. (2014) · Leukemia · doi:10.1038/leu.2014.241 · Cited by 40
Filipović, A., Lombardo, Y., Fronato, M., Abrahams, J. M., Aboagye, E. O., Nguyen, Q., d’Água, B. B., Ridley, A. J., Green, A. R., Rahka, E., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3119-z · Cited by 38
Chang, A. C. Y., Garside, V. C., Fournier, M., Smrz, J., Vrljicak, P., Umlandt, P., Fuller, M., Robertson, G., Zhao, Y., Tam, A., et al. (2014) · Developmental Dynamics · doi:10.1002/dvdy.24127 · Cited by 37
NOTCH Mutations: Multiple Faces in Human Malignancies
Mao, L. (2015) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-15-0063 · Cited by 35
Yao, J., Qian, C., Shu, T., Zhang, X., Zhao, Z., & Liang, Y. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.25332 · Cited by 34
Kolb, E. A., Gorlick, R. G., Keir, S. T., Maris, J. M., Lock, R. B., Carol, H., Kurmasheva, R. T., Reynolds, C. P., Kang, M. H., Wu, J., et al. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.23290 · Cited by 32
Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer
Steg, A. D., Burke, M. R., Amm, H. M., Katre, A. A., Dobbin, Z. C., Jeong, D. H., & Landen, C. N. (2014) · Oncotarget · doi:10.18632/oncotarget.2295 · Cited by 29
Weber, D., Heisig, J., Kneitz, S., Wolf, E., Eilers, M., & Gessler, M. (2014) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2014.11.004 · Cited by 27
Zhang, N. (2010) · Biologics · doi:10.2147/btt.s11021 · Cited by 27
Frequency and distribution of Notch mutations in tumor cell lines
Mutvei, A. P., Fredlund, E., & Lendahl, U. (2015) · BMC Cancer · doi:10.1186/s12885-015-1278-x · Cited by 24
New, Tolerable γ-Secretase Inhibitor Takes Desmoid Down a Notch
Hughes, D. P. M., Kummar, S., & Lazar, A. J. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1660 · Cited by 19
GSI promotes vincristine-induced apoptosis by enhancing multi-polar spindle formation
Singh, A., Zapata, M., Choi, Y. S., & Yoon, S.-O. (2013) · Cell Cycle · doi:10.4161/cc.26951 · Cited by 9
Cited by
Tungmunnithum, D., Thongboonyou, A., Pholboon, A., & Yangsabai, A. (2018) · Medicines · doi:10.3390/medicines5030093 · Cited by 1,969
Notch signaling pathway: architecture, disease, and therapeutics
Zhou, B., Lin, W., Long, Y., Yang, Y., Zhang, H., Wu, K., & Chu, Q. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00934-y · Cited by 1,114
Self-citationStem cell fate in cancer growth, progression and therapy resistance
Lytle, N. K., Barber, A. G., & Reya, T. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0056-x · Cited by 647
Almansour, N. M. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.836417 · Cited by 397
Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies
Medina, M. A., Oza, G., Sharma, A., Arriaga, L. G., Hernández Hernández, J. M., Rotello, V. M., & Ramirez, J. T. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17062078 · Cited by 333
Metadata
- Authors
- Yuan, X., Wu, H., Xu, H., Xiong, H., Chu, Q., Yu, S., Wu, G. S., & Wu, K.
- Venue
- Cancer Letters
- Publisher
- Elsevier BV
- Published
- 2015-12
- Volume
- 369
- Issue
- 1
- Pages
- 20-27
- ISSN
- 0304-3835 (ISSN-L)
- OpenAlex
- W2133708523
- Cited by
- 402
- References
- 83
- FWCI
- 16.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.